Literature DB >> 22322833

Delays in the diagnosis and treatment of non-small-cell lung cancer.

Ebru Sulu1, Oktay Tasolar, Huriye Berk Takir, Leyla Yagci Tuncer, Zuhal Karakurt, Adnan Yilmaz.   

Abstract

AIMS: To investigate patterns of delays among patients with non-small-cell lung cancer and to identify reasons for the delays.
METHODS: This prospective study included 101 patients with non-small-cell lung carcinoma. Clinical files of the patients were analyzed and a questionnaire was created to obtain data. Several time intervals and delays were determined for each patient. The reasons for the delays were also evaluated.
RESULTS: The mean time was 59.9 days for the application interval, 40.3 days for the referral interval, 16.4 days for the diagnostic interval, and 24.7 days for the treatment interval. The application interval was longer than 30 days (patient's delay) in 48 patients (48.5%). There was a doctor delay in 54 (53.5%) patients, a referral delay in 47 (46.5%) patients, a diagnostic delay in 37 (36.6%) patients, and a treatment delay in 57 (56.4%) patients. The mean total time was 119.6 days. Sixty-two patients (62.6%) had a total delay. The most common reason for patient's delay was neglect of symptoms by patients. A low index of suspicion for lung cancer was the most common cause for referral delay. The low performance of diagnostic tests was the frequent reason for diagnostic delay.
CONCLUSIONS: Patient's and doctor's delays were a common problem among patients with non-small-cell lung cancer. The rate of doctor's delay was higher than that of patient's delay. Several efforts such as education of the physicians and people about lung cancer should be made to reduce these delays.

Entities:  

Mesh:

Year:  2011        PMID: 22322833     DOI: 10.1177/030089161109700603

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  11 in total

1.  Level of Awareness of Various Aspects of Lung Cancer Among College Teachers in India: Impact of Cancer Awareness Programmes in Prevention and Early Detection.

Authors:  Abhishek Shankar; Shubham Roy; Abhidha Malik; G K Rath; P K Julka; Vineet Kumar Kamal; Keshav Barnwal; Sneha Upadhyaya; Rajan Singh; Vivek Srivastava
Journal:  J Cancer Educ       Date:  2016-12       Impact factor: 2.037

2.  Physician Related Delays in the Diagnosis of Lung Cancer in India.

Authors:  Krishnappriya Ramachandran; Balamugesh Thankagunam; Reka Karuppusami; D J Christopher
Journal:  J Clin Diagn Res       Date:  2016-11-01

Review 3.  Defining timeliness in care for patients with lung cancer: a scoping review.

Authors:  Adnan Ansar; Virginia Lewis; Christine Faye McDonald; Chaojie Liu; Muhammad Aziz Rahman
Journal:  BMJ Open       Date:  2022-04-07       Impact factor: 2.692

4.  PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-Labeled Ramucirumab.

Authors:  Haiming Luo; Christopher G England; Stephen A Graves; Haiyan Sun; Glenn Liu; Robert J Nickles; Weibo Cai
Journal:  J Nucl Med       Date:  2015-11-05       Impact factor: 10.057

5.  Endobronchial ultrasound - one year of experience in clinical practice.

Authors:  Marioara Simon; Bogdan Pop; Lacramioara Toma; Aletta Vallasek; Ioan Simon
Journal:  Clujul Med       Date:  2017-04-25

6.  Thioredoxin Reductase as a Novel and Efficient Plasma Biomarker for the Detection of Non-Small Cell Lung Cancer: a Large-scale, Multicenter study.

Authors:  Suofu Ye; Xiaofeng Chen; Yi Yao; Yueqin Li; Ruoxuan Sun; Huihui Zeng; Yongqian Shu; Hanwei Yin
Journal:  Sci Rep       Date:  2019-02-25       Impact factor: 4.379

7.  Changes in the Number of Newly Diagnosed Lung Cancer Patients Before and During the COVID-19 Pandemic: A Single-Center Experience.

Authors:  Şule Gül; Mehmet Atilla Uysal; Atilla Çifter; Elif Yelda Özgün Niksarlıoğlu; Deniz Bilici
Journal:  Turk Thorac J       Date:  2022-09

8.  Estimating and validating disability-adjusted life years at the global level: a methodological framework for cancer.

Authors:  Isabelle Soerjomataram; Joannie Lortet-Tieulent; Jacques Ferlay; David Forman; Colin Mathers; D Maxwell Parkin; Freddie Bray
Journal:  BMC Med Res Methodol       Date:  2012-08-17       Impact factor: 4.615

9.  2,3,5,4‑tetrahydroxy diphenylethylene‑2‑O‑glucoside inhibits the adhesion and invasion of A549 human lung cancer cells.

Authors:  Ming Xu; Cong Wang; Minglin Zhu; Xianguo Wang; Li Zhang; Jinping Zhao
Journal:  Mol Med Rep       Date:  2017-10-02       Impact factor: 2.952

10.  Health systems influence on the pathways of care for lung cancer in low- and middle-income countries: a scoping review.

Authors:  Ugochinyere I Nwagbara; Themba G Ginindza; Khumbulani W Hlongwana
Journal:  Global Health       Date:  2020-03-18       Impact factor: 4.185

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.